Skip to main content
. 2021 Jan 28;62(1):29. doi: 10.1167/iovs.62.1.29

Figure 1.

Figure 1.

miR-130a levels were increased in the orbit and in TED OFs treated with the PPARγ ligand 15d-PGJ2. (A) Thy1+ and Thy1– OFs were analyzed for miR-130a levels (n = 3; ***P < 0.001 using Student's t-test). (B) Fat tissues from different depots were analyzed for miR-130a. The level of miR-130a in non-orbital fat tissue was normalized to 1.0 (n = 4; *P < 0.05 using the Mann–Whitney non-parametric test for data that included outliers). (C) Fibroblasts were grown out of explanted fat tissues from the orbit and non-orbit fat depots. Expression of miR-130a was analyzed, and the level in non-orbital fibroblasts was normalized to 1.0 (n = 4 different non-OF strains; n = 11 different OF strains; ***P < 0.001 using Student's t-test). (D) OFs were treated with 5-µM 15d-PGJ2 or dimethylsulfoxide (DMSO) as control every second day for 8 to 10 days. Control OF miR-130a levels were normalized to 1.0 (n = 7 different TED OF strains; ****P < 0.0001 using Student's t-test).